Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Capsulution NanoScience
Berlin, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Capsulution NanoScience AG, a spin-off from the Max Planck Society, is a German nanobiotechnology company focused on pre-clinical solutions for pharmaceutical therapy, diagnostics, and drug delivery using its proprietary Layer-by-Layer (LBL) encapsulation technology. The company develops nanomaterial-based drug delivery systems and nanobiotech applications, with no evidence of current clinical trials or approved products.
- Therapeutic areas
- OtherEndocrinology
- Modalities
- NanoparticlePolymer-drug conjugate therapyProteinBiologic
- Industry
- Biotech
02
Partnerships
NascaCell (joint development program in target validation, drug discovery and therapy)
Beyond the preview
Go deeper on Capsulution NanoScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Capsulution NanoScience.